Life Sciences Archive » February, 2012

Life Sciences - February, 2012

219 articles

• Jury Finds Illumina Infringed LadaTech DNA Patent
• Consumer Groups Say Aneurysm Fixer Needs More FDA Tests
• Abbot Targets Amneal In Latest Suit Over Generic Niaspan
• Bill Would Create Registry Of Legit Web Pharmacies
• Indie Pharmacies Claim CMS Rule Stifles Competition
• Current Trends In Health Care Fraud Enforcement
• House Passes Bill To Nix High Court Eminent Domain Ruling
• Ex-Exec Can't Support FCA Claims, Pfizer Tells 1st Circ.
• Dainippon To Pay Up To $2.6B For Cancer Drug Developer
• GOP Lawmakers Lash Out At Employer Contraception Rule
• Bayer, Others Exit Price-Fixing Suit After High Court Win
• Families Toss Bid To Renew J&J, Omnicare Antitrust Suit
• Statins Carry Small Risk Of Diabetes, FDA Warns
• Merck Failed To Probe Diabetes Drugs For Risks: FDA
• Eisai Can't Pry Transcripts From 2003 Aventis Antitrust Suit
• Invalidity Claim To Be Tried In Pitt, Varian Patent Fight
• Arent Fox Lures Patent Whiz From Merchant & Gould
• Abbott Lodges New Zemplar Patent Suit Against Hospira
• Diagnostics Co. Alere To Acquire EScreen For $270M
• Marine Polymer — Take 2
• Doctors Urge Hill To Get Rid Of Payment Advisory Board
• FDA Warnings Don't Always Start Limitations Clock: NJ Court
• Mandarin Capital Triples Investment In Italian Pharma Co.
• With Insider Trading On Upswing, FBI Turns To Gordon Gekko
• Buying Groups Shook Down Vaccine Customers, Sanofi Says
• Mylan Ends Calif. Drug Price Inflation Claims For $57M
• FDA Rejects Preterm Birth Drug From Watson, Columbia
• Glenmark Recalls Birth Control Over Faulty Packaging
• Shareholders Win Cert. In Suit Over Matrixx Cold Medicine
• The Changing Face Of US Health Care
• Where Is The Corporate Integrity Agreement?
• SNR Denton Boosts IP Group With 3 Buchanan Patent Experts
• Hypertension Drug's Labeling Problems Prompt GSK Recall
• Disease Groups Beg Congress For Antibiotics R&D Boost
• Nestle Likely In Lead To Buy Pfizer's $10B Baby Food Line
• Nixon Peabody Lands Ex-Pillsbury Gov't Contracts Pro
• Warner Chilcott Subpoenaed Over Marketing, Off-Label Use
• Debtholders Can't Get $40M From US Oncology For Now
• Crowell Adds Dorsey Commercial Litigation Pro In Calif.
• Varian Hit With $37M Verdict In Pitt Patent Suit
• Regulatory Demands To Spur Health M&A in 2012: Report
• House Bill Aims To Rein In State Drug, Device Inspections
• GSK, Teva Face Antitrust Class Action Over Lamictal Deal
• Texas Drug Fraud Law Preempted In J&J Suit: 5th Circ.
• Faulty Vials Prompt Blood Pressure Med Recall
• Mounting Pressure For FCPA Reform
• Wash.'s Contraceptive Sales Rules Unconstitutional: Judge
• 11th Circ. Revives $69M Fraud Suit Against Medco
• Pfizer Unit Scores More Time In Ch. 11 For Asbestos Dealings
• Genetic Disorder Patients Take Aim At US Over Drug Shortages
• J&J Tries To Ease EU Concerns Over $21B Synthes Deal
• A Few Lessons On Managing Product Recalls
• Insurer Aims To Duck Coverage Of Omeros FCA Suit
• 2nd Circ. Bars Trusts From $138M Biovail, Investors Deal
• 8 States Probe Abbott's Marketing Of Anti-Seizure Drug
• $1.7B Humira IP Verdict Won't Get Supreme Court Review
• CMS Sunshine Rule Will Unfairly Burden Docs: AMA, Others
• Forest's COPD Drug May Have Added Heart Risks: FDA
• Allergan, Others Sought Pinkeye Treatment Monopoly: Suit
• High Court Mulls Translator Bills For Lawsuit Losers
• Cellectis Hit With New Genome Engineering IP Suits
• Mylan Settles Defamation Suits Against Pittsburgh Paper
• FDA Calls For Voluntary Reporting Amid Drug Shortages
• Teva To Pay $270M In Propofol Hepatitis Suits
• Genomma Bids $834M For Prestige Brands
• Schering-Plough Strikes $12.5M Deal In ERISA Suit
• Omnicare Abandons $441M Offer To Buy PharMerica
• New Kaye Scholer Product Heads Aim To Expand Group's Reach
• Novartis Must Note Blood Pressure Drug Risks On EU Labels
• J&J Unit Recalls Infants' Tylenol Over Dosing Device
• Amgen Employees Press 9th Circ. To Revive ERISA Action
• PhRMA, Others Urge CMS To Back Off On Sunshine Rule
• Bristol-Myers Subpoenaed By DOJ For Abilify Info
• Swiss Regulator OKs Apax's $2B Mobile Co. Buyout
• Increasing Access To Innovative Biomedical Technology
• In Promotional Labeling, Size Matters
• Law School, Meet Litigation PR ...
• New Bill Would Give FDA Greater Development, Review Tools
• Jury Convicts 4 In $29M Medicaid Billing Scheme
• CVS Escapes Class Action Over Health Data Sales
• Shionogi Scuttled Deal By Destroying Fenoglide Pills: Suit
• USPTO Gene Test Fight Pits Patients Against Patents
• Sens. Demand Info From Ben Venue Over Drug Shortage
• Genzyme Recalls Leukemia Meds Over Factory Concerns
• Calif. High Court Takes Up Cipro Pay-For-Delay Suit
• Jury Awards Promega $52M In Genetic Test Kit IP Suit
• Volcker Rule Draws Fire From Range Of Nonbank Cos.
• Probe Into FDA Monitoring Of Whistleblower Emails Expands
• 3rd Circ. Trims Injunction In Stryker Employee Poaching Suit
• Ky. Court Shuts Down Class Cert. In Vioxx Fraud Action
• M&A Pro Jumps To Arnold & Porter From Allen & Overy
• GOP Signals Fight Ahead Over Medical Device User Fees
• NuVasive Can't Boot Patent After $101M Infringement Verdict
• Illumina Investors Claim Goldman Bias In Suit Over Roche Bid
• Colgate, Church & Dwight Settle Toothbrush-Package Suit
• Graceway Settles Claims With GTCR For $6M
• HHS, DOJ Recoup Record $4.1B From Health Fraud In FY 2011
• SAC Ramps Up Apple Stake To $433M In 4th Quarter
• Lawmakers Press FDA To Get Tough On Drug Trial Reporting
• Counterfeit Avastin Found In US, Roche Says
• Cell Therapeutics Settles Investor Lawsuit For $19M
• EDG Partners Closes 2nd Health Care Fund At $178M
• Genzyme, Insurer Settle Coverage Suit Over $64M Deal
• CMS Floats 60-Day Medicare Overpayment Refund Rule
• USPTO Patent Review Rules To Trigger Discovery Battles
• AlloDerm Insurer Sues Over Coverage For Alleged Injuries
• 'Independent Practice,' Collective Enforcement
• Omnicare Dodges Investor Action Over Kickback Claims
• Biogen To Spend $75M For Fibrosis Drug Co. Stromedix
• Insurer Wants Out Of J&J Supplier's Bug Infestation Suit
• Facebook, Others Weigh In On Fed. Circ. Intervening Rights Case
• Obama Budget Would Trim Health Entitlements By $350B
• Obama's 2013 Budget Targets Pay-For-Delay Deals
• Dental Device Maker Halts Operations Amid FDA Warnings
• Judge OKs 3 New Bellwethers In NuvaRing MDL
• Proskauer Fights To Dismiss J&J Heir's $140M Suit
• Drug Industry Balks At Obama's Budget Proposals
• Medtronic Pushes For Royalties In NuVasive Patent Row
• RI Hospital Puts Up $5M To End False Claims Allegations
• US, 4 States Join CVS Caremark Insurance Fraud Action
• Weil Gotshal Grabs Dechert Litigation Duo For NY Office
• Express Scripts, Medco Send FTC More Info On $29B Merger
• Examining Comcast's Calif. SBE Loss
• Shook Hardy Wields Largest Product Liability Group
• Mylan Must Shell Out $18M To Sunovion In Xopenex Patent Suit
• Delays Cost Cephalon TRO In Anti-Epilepsy Patent Suit
• Biosimilar Guidance Silent On Industry's Biggest Questions
• Merck, Bayer Target Watson Over Generic Beyaz Birth Control
• Baker Sports World's Biggest M&A Practice
• Mylan Escapes 6 Cases In Darvocet, Darvon MDL
• SNR Denton Leads Pack With Largest Privacy Group
• Latham & Watkins Dominates White Collar Arena
• DLA Piper Tops The List Of Megafirms
• US Sues Dallas Drug Compounder Over 3 Colchicine Deaths
• Pfizer Bests Investor Suit Over Alzheimer's Drug Trial
• Patient Wants High Court To Take Up Genzyme Negligence Suit
• Sens. Press OMB For Delayed Medical Device Rule
• FDA's Stepwise Approach To Demonstrating Biosimilarity
• Judge Misread Patent Claims, Sanofi Tells Fed. Circ.
• Jury Clears Sigma In $172M Medical Pump Patent Suit
• Case Study: Messner V. Northshore
• FDA Releases Guidance On Biosimilar Approvals At Last
• Ex-Leo Pharma Sales Reps Launch OT Class Action
• No Quick Appeal For Chinese Cos. In Vitamin C MDL
• Ex-Allergan President Escapes Investor Suit Over Exec Pay
• AstraZeneca Can't Block Generic Crestor: Fed. Circ.
• 9th Circ. Axes Lawsuit Over Stores' Drug Pricing Role
• Drug Cos. To Fund FDA Generics Reviews Under New Bill
• Catholic TV Network Sues US Over Birth Control Mandate
• Ex-Takeda Exec Settles SEC Insider Trading Claims
• Ex-Citigroup Exec Hits Abbott With Humira Cancer Suit
• No Quick Win For Ex-KV Pharma CEO On Criminal Costs
• How They Won It: Ropes & Gray Rescues Stryker Biotech
• FDA Panel Votes Against Amgen's Xgeva For Prostate Cancer
• Drug Co. Dava Pays $11M To End Medicaid Rebate Suit
• Ernst & Young Censured, Fined $2M Over Faulty Audits
• Mylan Can't Launch Doryx Generic Just Yet
• Popular Acid Reflux Drugs Can Trigger Infections: FDA
• Insurer Dodges Malpractice Liability Over Unfiled Suit
• 5th Circ. Frees Courts To Pick Fee Method In Class Deals
• FDA Faces Renewed Battle Over Plan B Age Restrictions
• Watson, J&J Settle Over Birth Control Generic
• Qui Tam Trends In 2011, Predictions For 2012
• 11th Circ. Won't Hear Venue Question In Denture MDL
• Illumina Board Urges Investors To Reject $6B Roche Bid
• Fed. Circ. Finds Exception To Late Interference Claims
• Bayer, Merial Flea Product Class Actions Merged In Ohio
• Hospitals Will Pay DOJ $12M To End Medicare Fraud Claims
• MDL Panel Sends Surgical Mesh Battles To W.Va.
• BioMed Realty Brings In Mass. Office Space For $119M
• Judge Upholds FDA Approval Of Generic Lovenox
• MoFo Adds Howard Hughes GC To Life Sciences Team
• DOL Tells High Court Drug Sales Reps Deserve OT Pay
• Class Actions And Causation: Duking It Out In 2012
• Pfizer Faces Antitrust Suit Over Generic Lipitor Delay
• Fed. Circ. Lifts Lupin Ban In Generic Fortamet Fight
• Wake Forest Blasts Jury Interrogatories In Fed. Circ. IP Case
• Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
• Greenberg Adds Reed Smith Atty To Health Products Group
• RiverVest Investor Payouts Off $1B Sales Top Charts
• Mylan, Shire Battle Again Over Generic Vyvanse
• IRS Lays Out Plan For New Medical Device Tax
• Who's A Federal Contractor? You Just Might Be
• Smith & Nephew Pays $22M To Settle US Bribery Allegations
• BioSante Female Libido Drug Hype Was Fraudulent: Suit
• Cancer Drug Firm Duped Investors In $26M Offering: Suit
• Sen. Looks To Close Cost Gap In Hospitals' Implant Buys
• Pop Star Drake Sued By Ex-Girlfriend For Song Royalties
• Columbia Labs Sued Over Drug-Related Stock Drop
• GAO Scraps Protests Over $73M Medicare Auditing Contract
• Trends In M&A, Spin-Offs, Hostile Deals And PE
• Impax, Teva Put Generic-Wellbutrin MDL To Bed
• Senate Bill Would Streamline FDA's New Device Reviews
• 7th Circ. Shuts Down Abbott Workers' Benefit Appeal
• The Trouble With 'Confidential Witness' Allegations
• Sister Sledge Hammers Warner Over Download Royalties
• Highlighting 'Pay For Delay' Concerns
• A Little 'Guidance': All You Need For Preemption?
• EU Seeks Deeper Study Of Faulty Breast Implants
• States Need Guidelines When Hiring Outside Attys: Ex-AG
• Grassley Grills FDA Over Whistleblower Treatment
• Dentsply Blames Lewis & Roca For Contract Case Loss
• Sen. Blasts Express Scripts, Medco Deal On Antitrust Fears
• Angioblast Loses Contract Counterclaims Against UBS
• Ex-Reed Smith Life Sciences Pro Jumps To Hogan Lovells
• Bill Targets 'Loophole' In FDA Device Approval Process
• Witness Must Testify In Medtronic Off-Label Suit: Judge
• FCA Haul Topped $8.8B In Past 3 Years, Holder Says
• Kappos Says Prior Use Rule Shouldn't Be Changed For Now
• Astellas Can't Shake MDL Over Generic Prograf Delays
• House To Subpoena VA Docs Over Off-Contract Drug Buys
• 5th Circ. Allows State Claims In Stryker Implant Suit
• FDA Aims To Boost Inspections Of Foreign Drugmakers
• Pfizer Recalls Birth Control Pills After Packaging Mix-Up
• Mitigating Risk In Mass Nano Torts
• Push To Split Chairman, CEO Roles Gains Traction
• The Global Reach Of Stem Cell Research Patents
• Crowell Adds 3 Kilpatrick Townsend Drug IP Specialists
• SEC Panel Proposes Easing Regulation On Small Businesses